Printer Friendly

DEPRENYL USA ANNOUNCES NO CHANGE AT COMPANY TO ACCOUNT FOR SHARE PRICE PRESSURE

 DEPRENYL USA ANNOUNCES NO CHANGE AT COMPANY TO ACCOUNT
 FOR SHARE PRICE PRESSURE
 TORONTO, Ontario, Sept. 21 /PRNewswire/ -- Deprenyl USA Inc. (NASDAQ: DUSA Common Stock; DUSAW Warrants. TSE: DPU Common Stock; DPU.WT Warrants) wishes to confirm that there is no material change to any of its operations nor any other material information which would have caused the recent decrease in the price of its securities.
 Dr. D. Geoffrey Shulman, president, indicated that the trading activity of Deprenyl USA Inc. securities may have been effected by a press release issued on Sept. 17, 1992, by Deprenyl Research Ltd. and Bone Health Inc. regarding a matter which does not affect Deprenyl USA, Inc.
 Deprenyl USA, Inc. is a development stage company established to develop prescription pharmaceutical products for all markets, including the United States and Canada, primarily in the field of photodynamic therapy (PDT), which combines the use of a pharmaceutical product with exposure to light to induce a therapeutic effect. The company is initially developing aminolevulinic acid ("ALA") PDT for dermatological indications such as pre-cancerous actinic keratoses and basal cell skin cancers; and development is proceeding on schedule. The Company has assets in excess of $15,000,000, primarily in United States government securities, which was raised in connection with its initial public offering in January 1992.
 -0- 9/21/92
 /CONTACT: D. Geoffrey Shulman, M.D., FRCPC, president and CEO, or Edward L. Foster, CA, chief financial officer, 416-537-1070, 416-537-4372, or fax 416-537-0258, both of Deprenyl USA (Toronto Office); Joseph P. Castelli, vice president, 201-299-9070, or fax, 201-335-0372 of Deprenyl USA (New Jersey office); or Jim Tolan, senior vice president of O'Connor Biro & Associates, 708-498-2284, of fax, 708-498-3144, for Deprenyl USA/
 (DPU) CO: Deprenyl USA Inc. ST: Ontario IN: MTC SU:


SH -- NY017 -- 1487 09/21/92 08:47 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 21, 1992
Words:301
Previous Article:NOEL GROUP COMPLETES DISTRIBUTION OF GLOBAL, VISX AND GARNET SHARES
Next Article:HURRICANE ANDREW RESTORATION OVERVIEW
Topics:


Related Articles
CANGUARD ANNOUNCES PRIVATE PLACEMENT AND APPOINTMENT OF FISCAL AGENT
DEPRENYL RESEARCH COMMENTS ON STOCK PRICE
DEPRENYL RESEARCH CHAIRMAN ISSUES STATEMENT ON SELL ADVISORY
DEPRENYL USA ANNOUNCES CONDITIONAL LISTING ON TORONTO STOCK EXCHANGE
DEPRENYL RESEARCH NOTES NO CHANGE IN COMPANY TO ACCOUNT FOR CURRENT PRESSURES ON SHARE PRICE
DEPRENYL RESEARCH ANNOUNCES FINAL PROSPECTUS OF BONE HEALTH INC.
DEPRENYL RESEARCH LTD. & BONE HEALTH INC. TO AWAIT FULL ANALYSIS OF CLINICAL TRIALS BEFORE ISSUING FINAL AMENDMENTS TO PROSPECTUS
DEPRENYL USA, INC. SIGNS AGREEMENT ON ADDITIONAL PHOTODYNAMIC CANCER FIGHTING COMPOUNDS
DEPRENYL USA CLASS A WARRANTS MAYBE EXERCISED UNTIL APRIL 19, 1993
DEPRENYL RESEARCH REPORTS EARNINGS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters